TrialBlood cancer journal2025

Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma.

Lixia Sheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.